3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Colorectal Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Solid Cancer
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Astrocytoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Temozolomide
12
Bevacizumab
8
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
5
temsirolimus
3
Surgical Procedures, Operative
3
Irinotecan
3
IL13-PE38
3
veliparib
2
pembrolizumab
2
etoposide phosphate
2
Vorinostat
2
Specimen Handling
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy, Conformal
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Imatinib Mesylate
2
Genetic Therapy
2
Everolimus
2
Cetuximab
2
Carmustine
2
Cancer Vaccines
2
trastuzumab deruxtecan
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
terameprocol
1
sonidegib
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Astrocytoma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled